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Abstract
Introduction
In a perspective of economic constraints the prioritizing of patients to IFN-free regimens is
mainly based on the determination of liver stiffness by transient elastography (TE). Being a
continuous variable the interpretation of TE results requires the identification of cut-off val-
ues, to date set to maximize diagnostic accuracy even if such values should be better
based on more helpful outcome prediction endpoints.
Aim
To define the TE cut-off values in different clinical scenarios, including new IFN-free regi-
mens, and to balance the clinical benefits versus harms in treated and untreated patients.
Methods
We assessed the accuracy of TE in staging 728 consecutive HCV patients and the distribu-
tion of TE values in 1,001 blood donors. Ten experts quantified the expected harm/benefit
ratio for 6 scenarios resulting from 2 stages of liver disease (F2 or F3) and 3 treatment
regimens: PEGIFN+ribavirin, PEGIFN+RBV+first-generation protease inhibitor, and IFN-
free regimens. The optimal TE cut-off values were identified using the Metz equation.
Results
The estimated mean expected harm/benefit ratio for IFN-free regimens was 1/8.3 in
patients with F2 and 1/10 in those with F3. The resulting optimal cut-off values were
respectively 4.5 kPa with sensitivity at 99% and specificity at 12%, and 6.8 kPa with sensi-
tivity at 94% and specificity at 41%. These cut-off values are lower than those maximizing
accuracy and allow to reduce the number of false negative results.
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Conclusions
The optimal TE cut-off values to prioritize patients for IFN-free regimens, are sensibly lower
than those used to maximize diagnostic accuracy.
Introduction
The limitation of resources for most national health services precludes the antiviral treatment
of all HCV patients and leads to the need of prioritizing treatment mainly for those patients at
highest risk for disease complications.
Especially for IFN-free regimens, which are highly effective and safe but particularly expen-
sive, the prioritization is mainly decided on the basis of the stage of liver fibrosis, assessed by
liver histology, which in the last few years has been almost completely substituted by the assess-
ment of LS via transient elastography.
In order to interpret the results of transient elastography and identify whether the disease
is or is not present (i.e., the stage of liver fibrosis), TE being a continuous variable, a cut-off
should be chosen, habitually on the basis of diagnostic accuracy. In fact, diagnostic studies usu-
ally concentrate on diagnostic accuracy, i.e. the concordance between test results and a refer-
ence standard, yet this approach does not necessarily translate into better clinical outcomes,
which can only be assessed after a new test has been introduced into clinical practice [1]. If test
results are expressed on a continuous scale, identifying the presence or absence of the target
disease is based on a cut-off value usually chosen on the basis of accuracy (i.e. the best balance
between sensitivity and specificity).However, an alternative and more clinically oriented
approach would be to consider the downstream effects of testing in terms of false negative and
false positive results: such an approach would identify those patients with the minimum degree
of “abnormality” requiring treatment. In this scenario, the disease would be regarded in terms
of risk prediction, and diagnosis would play a decision-making role [2].
The measurement of liver stiffness (LS) by means of transient elastography (TE) enables
the staging of liver disease severity, particularly for the most frequent chronic infection, i.e. the
hepatitis C virus (HCV), and supports the making of decisions on its possible treatment [3]
as LS is a validated indicator of liver disease severity, which is a criterion to access antiviral
treatments. The currently used TE cut-off values for ‘significant’ and ‘severe’ liver disease are
respectively 7.65 and 9.6 kPa, following their maximal concordance with the findings of the
liver histology reference standard [4–7]. However, the TE cut-off values for maximizing the
possible treatment benefits potentially change depending on the available therapeutic options:
therefore it becomes necessary to define new values for supporting the eventual administration
of interferon (IFN)-free anti-HCV regimens.
Materials and Methods
HCV patients
With the aim of defining the accuracy of TE-based LS measurements, our study considered all
of the consecutiveHCV-positive patients who underwent a liver biopsy for the staging of
chronic hepatitis C at the A.M. & A. Migliavacca Center for Liver Disease in Milan (Italy)
betweenOctober 2005 and October 2014. The inclusion criteria were: serum alanine amino-
transferase (ALT) levels to be persistently or intermittently >1.5 times the upper reference
limit in the presence of serummarkers of HCV infection; patients with ascites were excluded.
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Abbreviations: B/H ratio, benefit/harm ratio; IFN-
free regimens, interferon-free regimens; PEGIFN
+RBV+first-generation, peginterferon + ribavirine
first-generation protease inhibitor; ROC, receiver
operating characteristic curve; TE, transient
elastography.
The study protocol was approved by the Ethics Committee of Fondazione IRCCSCa’ Granda
OspedaleMaggiore Policlinico, Milan (ref. 78/2005). The patients fulfilling the inclusion crite-
ria were enrolled after obtaining their written informed consent.
The patients underwent TE on the same day but before liver biopsy. The right lobe of the
liver was targeted with access through an intercostal space, while the patient was in a dorsal
decubitus position with his/her right arm in maximal abduction. A portion at least 6 cm thick
and free of large vessels was identified under FibroScan1 ultrasound (US) guidance. Only the
examinations with at least 10 valid measurements and a success rate of at least 60% (calculated
as the ratio between the number of valid measurements and the total number of measure-
ments) were considered reliable. The median of all the successfulmeasurements was expressed
in kilo Pascal (kPa) and considered representative of LS in a given patient, but only if the inter-
quartile range (IQR) of all the valid measurements was less than 30% of the median value [5].
The liver biopsies were carried out under US guidance, using a 16 Gauge modifiedTru-Cut
needle (Biomol, HS, Rome, Italy), to obtain samples longer than 2.5 cm; in the case of shorter
samples a second biopsy was performed. Liver fibrosis and necroinflammatory activity were
semiquantitatively evaluated by METAVIR scoring [8, 9]. Mean and median values, standard
deviations (SD) and ranges were calculated for descriptive purposes.
Healthy controls
In order to set the upper reference limits for LS, we examined a consecutive series of blood
donors attending the Department of Transfusion Medicine and Hematology at the A. Manzoni
Hospital in Lecco (Italy), where behavioral, clinical and laboratory examinations of about
15,000 candidate blood donors are carried out every year. The study was proposed to a random
sample of donors (those attending the center to donate blood on Mondays, Tuesdays and
Wednesdays) with the aim of enrolling 1,000 subjects who had no medical or behavioral con-
traindication to blood donation and were negative to the serological and nucleic acid testing
(NAT) markers of HBV, HCV and HIV-1/2 and to a hemagglutination test for syphilis. The
laboratory panel included: a complete blood count, serum liver biochemistries, and glucose,
cholesterol and triglyceride concentration. The patients’ weight and height were measured in
order to calculate their bodymass index (BMI), and a 24.9 kg/m2 BMI was considered the
upper limit for healthy weight. LS was assessed using a FibroScan1 unit (Echosens, Paris,
France) and the aforementioned procedure. The results were expressed as median values and
5th 25th 75th and 95th percentiles.
Harm/benefit ratio estimation
A questionnaire was submitted to 10 liver units in Italy (3 in Milan, and one each in Lecco, Ber-
gamo, Parma, Bologna,Naples, Messina, and Palermo) requesting their clinical (or holistic)
assessment of the benefit/harm (B/H) ratios of three possible anti-HCV treatments for two dif-
ferent stages of chronic hepatitis C (genotype 1), i.e. pegylated IFN [PEGIFN] + ribavirin
[RBV], PEGIFN + RBV + first-generation protease inhibitor [PI], and IFN-free regimens. The
word “harm” was used in order to ensure that the requested judgment would take no financial
costs into account. The term” benefit” refers to the subjective evaluation of how to prevent cir-
rhosis development, its complications and liver-related death.
The questionnaire was preceded by the sharing of background information defining benefit
and harm, and including two non-hepatological clinical examples (pulmonary embolism and
sore throat). “Benefit” was defined as the net advantage of being treated in the presence of the
target disease (i.e. a true positive case), while “harm” was defined as any damage due to treat-
ment in the absence of the target disease (i.e. a false positive). The B/H ratio was expressed as a
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numerical ratio (without units) representing the relative weight of the advantages vs. disadvan-
tages of treatment. [10]
Statistical methods
Receiver operating characteristic (ROC) curves of LS in the two target conditions (severe and
significant liver fibrosis) were obtained from the available cohort of HCV patients using a
bi-normal model that assumed the normal distribution of log-transformed LS values. The
overall accuracy of the LS measurements was estimated using the area under the ROC curve
(AUROC). Subsequently, and as suggested by Metz [11], the optimal cut-off value (i.e. the
value that maximizes the overall expected benefit) for each of the six scenarios was identified as
the point on the ROC curve at which the slope of the curve is equal to:
H
B

1   pðDÞ
pðDÞ
where H is harm, B benefit and p(D) the prevalence of the target condition. The cut-off values
corresponding to the maximum value of Youden’s index (i.e. maximum sensitivity+specificity-
1) were also identified [12].
A summary table was also produced showing the effects of different cut-off values in a vir-
tual cohort of 1,000 patients with the same prevalence of severe fibrosis as in our sample.
Results
Definition of LS normal values
LS measurement was proposed to 1,014 blood donors: 1,001 accepted and were enrolled; valid
measurements were obtained in 977 (97.6%, 95% CI 96.6%‒98.5%). Table 1 shows the distribu-
tion of LS values by gender: the 50th and 95th percentiles were respectively 4.4 kPa and 7.6 kPa.
Forty-eight donors showed values above the upper 95th percentile: the presence of liver dis-
ease was excluded in 31 (68%) on the basis of a clinical work-up consisting of a physical exami-
nation, liver US, liver enzymemonitoring, the measurement of anthropometric indices, and re-
evaluation of their medical history. Seventeen individuals (32%) had signs of chronic liver dis-
ease, including steatosis, increased liver enzyme levels, obesity, and glucose intolerance. All but
two people had BMI>25 kg/m2.
Analysis of the LS values in patients with chronic HCV-related liver
disease
In the cohort of 787 eligible patients with chronic HCV-related liver disease, six people refused
to undergo liver biopsy or had some contraindication, while 781 patients consecutively under-
went TE scanning followed by ultrasound-guided liver biopsy during the same session. The
728 patients who satisfied the study criteria, were 419 males and 309 females, with a mean age
of 51 years, a mean BMI of 24.3 kg/m2, and a mean LS value of 10.8±8.9 kPa (range 2.5–75
kPa). Table 2 summarizes the patients’ main clinical and laboratory data. Examination by TE
was unsuccessful in 53 patients (7%) because of stiffnessmeasurement failure (n = 8) or unreli-
ability (i.e. a success rate<60% and/or IQR>30% of validated measurements, n = 45).
All the liver specimens obtained by liver biopsy satisfied the predefined reference standard
adequacy criterion, i.e. 12 complete portal tracts.
Fig 1 shows the ROC curves of the overall diagnostic accuracy of the LS measurements for
the diagnosis of significant (F2) and severe fibrosis (F3): the AUROCs were respectively
0.87 and 0.91.
Transient Elastography Cut-Off to Maximize Antiviral Treatment Benefits
PLOS ONE | DOI:10.1371/journal.pone.0164452 October 10, 2016 4 / 12
Estimation of H/B ratios
All the 10 hepatology centers receiving the questionnaire, completed and returned it. Table 3
shows the H/B ratios that each center assessed for each scenario and their mean values.
Definition of the LS cut-off value maximizing the expected benefit
Taking into account the prevalence of the target disease (significant or severe fibrosis) and the
mean H/B ratios, the corresponding optimal cut-off –value was calculated for each scenario as
described in Methods. Table 4 shows the mean H/B ratios and the six different optimal cut-off
values. The optimal cut-off points in the ROC curves for significant and severe fibrosis are
shown in Fig 1. In Table 5 with regard to the 5th and 6th scenario we summarized the accuracy
of three different LS cut-off values: i.e. the value calculated to maximize benefit [11], the value
in use (derived from a meta-analysis of accuracy) [4], and the value derived post hoc on the
basis of our results using the maximum of Youden’s index.
Significant fibrosis (F2)—5th scenario. Considering a virtual cohort of 1,000 patients,
and assuming the same prevalence of fibrosis F2 (53.2%) as that observed in our cohort of
patients with chronic hepatitis C, and using the cut-off value of 4.5 kPa maximizing the benefit
of IFN-free regimen, we would obtain 6 false negative and 413 false positive results. With the
usual cut-off value of 7.65 kPa we would have obtained 73 false negative and 167 false positive
results. Finally, with the cut-off value at 9.3 kPa obtainedmaximizing Youden’s index we
would obtain 138 false negative and 81 false positive results (Table 5).
Severe fibrosis (F3)—6th scenario. Considering a virtual cohort of 1,000 patients and
assuming the same prevalence of fibrosis F3 (30.5%) as that observed in our cohort of
Table 1. Distribution of liver stiffness measurements in 1,001 blood donors.
Gender No. of subjects Liver stiffness values (kPa)
Total With valid measurements* Percentiles
5th 25th 50th 75th 95th
Males 581 575 3.2 4.0 4.6 5.6 7.8
Females 420 402 2.8 3.4 4.1 4.8 7.4
Overall 1,001 977 3.0 3.8 4.4 5.3 7.6
*Invalid measurements were obtained in 24 subjects (2.4%, 95% CI 1.4%–3.4%): 6 males (1.03%, 95% CI 0.4%–2.2%) and 18 females (4.1%, 95%CI
2.4%–6.4%).
doi:10.1371/journal.pone.0164452.t001
Table 2. Demographic and clinical characteristics of HCV patients concomitantly undergoing TE
and liver biopsy assessments of liver stiffness.
Variables Patients (n = 728)
Males/females 419/309
Mean age ± SD (range), years 51±12 (23–71)
Mean BMI ± SD, kg/m2 24.3±3.6
Mean ALT ± SD (range), IU/L (n.v. <38) 98±95 (14–567)
Mean AST± SD (range), IU/L (n.v. <38) 92±89 (10–678)
Mean GGT± SD (range), IU/L (n.v. <50) 68±76 (7–546)
Platelet count± SD (range), 109/L 210±73 (51–638)
Liver stiffness± SD (range), kPa 10.8±8.9 (2.5–75)
F2 (prevalence) 387 (53.2%)
F3 (prevalence) 222 (30.5%)
doi:10.1371/journal.pone.0164452.t002
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Fig 1. Receiver operating characteristic (ROC) curves, areas under the curve (AUROC), and cut-off values in the
different scenarios for significant fibrosis (Panel A) and severe fibrosis (Panel B).
doi:10.1371/journal.pone.0164452.g001
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patients with chronic hepatitis C, and using the cut-off value of 6.8 kPa maximizing the benefit
of IFN-free regimen, we would obtain 20 false negative and 408 false positive results. Whereas
with the usual cut-off of 9.6 kPa we would have obtained 55 false negative and 98 false positive
results. Finally, with the cut-off at 10.0 kPA obtainedmaximizing Youden’s index we would
obtain 61 false negative and 83 false positive results (Table 5).
Discussion
The access of patients to antiviral treatment, especially after the introduction of the highly
effective but extremely expensive IFN-free regimens, is mainly based on the assessment of liver
fibrosis stage.
The consideration that a good level of cost effectiveness is obtained treating patients at an
early stage of disease [13] and that chronic HCV infection also causes significant extra-hepatic
morbidly [14], leads to the requirement of redefining the TE cut-off, switching frommerely
diagnostic criteria to disease-outcome-predicting endpoints, this implying an extensive hepato-
logic clinical judgment.
TE cut-off values actually serve the purpose of maximizing diagnostic accuracy according to
Youden’s index, which is based on the sum of true positive and true negative results [12]. In
this scenario, the downstream clinical consequences of testing are not explicitly evaluated, and
the effect of the false positive and false negative results is implicitly considered equivalent.
However, when there is the aim of setting a cut-off value in order to support clinical decision-
making, the consequences of false results (i.e. from treating subjects who do not have the target
Table 3. Estimates benefit/harm ratios for the six scenarios estimated by 10 Italian hepatology centers.
1st F2
PEG-IFN
+ RBV
2nd F3
PEG-IFN
+ RBV
3rd F2 PEG-IFN + ribavirin
+ first-generation protease
inhibitors
4th F3 PEG-IFN + RBV + first-
generation protease inhibitors
5th F2 IFN-free
regimens
6th F3 IFN-free
regimens
Palermo 2 3 3 4 8 10
Bergamo 6 7 4 7 10 10
Milan 1 1.33 3 1 2.25 4 9
Naples 2 3 3 4 5 10
Parma 5 3 2 5 9 10
Milan 2 6 6 7 8 10 10
Messina 2 3 3 4 9 8
Lecco 2.5 2.75 2 1.44 17 19
Milan 3 1.75 5 1.4 3.3 7 10
Bologna 3 1.5 1.5 2 4 4
Mean
value
3.1 3.7 2.8 4.1 8.3 10
doi:10.1371/journal.pone.0164452.t003
Table 4. Harm/benefit ratios and corresponding liver stiffness cut-off values in all the scenarios.
1st F2 PEG-IFN
+RBV
2nd F3 PEG-IFN
+RBV
3rd F2 PEG-IFN+RBV
+PI
4th F3 PEG-IFN+RBV
+PI
5th F2 IFN-
free
6th F3 IFN-
free
H/B ratio* 1/3.1 1/3.7 1/2.8 1/4.1 1/8.3 1/10
LS values
(kPa)
6.1 9.4 6.4 9.2 4.5 6.8
*mean value of the 10 liver units.
doi:10.1371/journal.pone.0164452.t004
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condition and or from not treating subjects who have it) should be weighed, and the cut-off
value should vary depending on the treatment options to avail.
Using chronic hepatitis C as an example, we have showed that the diagnostic test cut-off val-
ues can be definedwith the aim of maximizing the benefit of treatment rather than overall
diagnostic accuracy. The decisions concerning the treatment of patients with chronic hepatitis
C are driven by the stage of fibrosis and liver disease severity [3, 13, 15–19] which can be accu-
rately and safely assessed by measuring LS as an alternative to percutaneous liver biopsy. Fur-
thermore, the results can be expressed as continuous variables, thus enabling the categorization
of multiple cut-off values, which can be optimized for different clinical scenarios [8]. We have
obtained two LS ROC curves for diagnosing significant and severe fibrosis/liver disease in
patients with chronic hepatitis C, using liver histology as the reference standard. We have then
identified the cut-off values maximizing treatment benefit in 6 therapeutic scenarios (Fig 1) by
taking into account the harm/benefit ratio of the treatment defined by a group of expert clini-
cians and the prevalence of the target condition [6].
In the scenarios of IFN-based treatment, which is less effective and more harmful than IFN-
free regimens, we have identified cut-off values that are close to those currently in use as calcu-
lated by maximizing diagnostic accuracy (7.65 kPa for significant fibrosis and 9.6 kPa for severe
fibrosis) [4]. However, when the scenarios changed to those of IFN-free regimens, the optimal
cut-off value decreased to 6.8 kPa when the aim was to treat patients with severe fibrosis, this
figure being close to the upper reference limit obtained on the basis of the distribution of LS
values in healthy blood donors (7.6 kPa) (Table 2). This indicates that, when highly effective
and safe treatment options are available, clinicians favor sensitivity over specificity and end up
electing for treatment patients with any degree of fibrosis. Furthermore, when the threshold
was lowered in order to include patients with significant fibrosis, the optimal cut-off value (4.5
kPa) was close to the 50th percentile of the healthy donors, thus indicating that all people are
potentially treated regardless of their LS values because the possibility of treating carriers with-
out any degree of fibrosis is clinically acceptable.
As expected, our data shows that, in the case of a very low H/B ratio such as that of IFN-free
regimens, the penalty from being false positive is more acceptable than that from being false
negative. Furthermore, if the H/B ratio is close to one (as in the case of the two obsolete
Table 5. Liver stiffness measurement. Effects in a virtual cohort of 1,000 patients with chronic hepatitis C in the 5th scenario (significant fibrosis
and interferon-free regimens) and 6th scenario (severe fibrosis and interferon free regimens).
5th SCENARIO F2 (significant fibrosis)
Cohort n = Prevalence F2 Sensitivity Specificity TP FP FN TN
Benefit cut-off (4.5 kPa) 1000 53.2% 0.990 0.118 526 413 6 55
Cut-off in use (7.65 kPa) 1000 53.2% 0.864 0.645 459 167 73 301
Youden (9.3 kPa) 1000 53.2% 0.741 0.827 394 81 138 387
6th SCENARIOF3 (severe fibrosis)
Cohort n = Prevalence F3 Sensitivity Specificity TP FP FN TN
Benefit cut-off (6.8 kPa) 1000 30.5% 0.937 0.413 285 408 20 287
Cut-off in use (9.6 kPa) 1000 30.5% 0.82 0.859 250 98 55 597
Youden (10.0 kPa) 1000 30.5% 0.801 0.881 244 83 61 612
Benefit cut-off: cut-off defined according to the Metz method.
Cut-off in use: cut-off derived from previous studies.
Youden; cut-off derived according to Youden’s Index.
Sensitivity and specificity assessed using liver biopsy as the reference standard.
TP: true positives, FP: false positives, FN: false negatives, TN: true negatives.
doi:10.1371/journal.pone.0164452.t005
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treatments), the same weight is attributed to false positive or negative test results, and the same
cut-off value can maximize both accuracy and treatment benefit.
The application of the new cut-off values in a virtual cohort of 1,000 patients with chronic
hepatitis C and a 30% prevalence of severe fibrosis increases the number of true positive results
to 35 (with the consequent benefit of IFN-free treatment) at the expense of 310 more false posi-
tive results: i.e. the penalty from being false negative clearly outweighs the penalty from being
false positive (Table 4). Similarly, in the case of significant fibrosis, the new cut-off value would
lead to IFN-free treatment for further 313 patients (67 true and 246 false positive).
The estimated cut-off values obtained using Metz’s equation [11] has not only depended on
the H/B ratio, but also on the prevalence of the target condition (severe or significant fibrosis)
as a different prevalence leads to a different number of false results: in the case of a higher prev-
alence, there are usually more false negative results, and in the case of a lower prevalence, there
are likely to be more false positive results. However, the prevalence of severe and significant
fibrosis among the patients with chronic hepatitis C of this study appears to be quite similar to
the rates observed also by other centers [9–12], and therefore the LS cut-off estimates are
mainly due to the H/B ratios of the treatment options.
One major advantage of the clinically oriented approach described in this study is that any
center can set its own cut-off value to reflect the prevalence of the target condition and balance
the expected rates of false positive and negative results against treatment efficacy; the values
could be even adjusted to an individual patient’s characteristics or preferences [20]. For exam-
ple, a patient’s age which has not been taken into account in the 6 scenarios presented here for
the sake of simplicity, is an important factor related to life expectancy and benefit estimation,
and can be included in the model. Furthermore, the average of the H/B ratios estimated by dif-
ferent centers can help define homogenous rules against resource constraints, as in the case of
very expensive IFN-free regimens. This approach has been suggested over 15 years ago for
tuberculosis testing, mammography and palpation for breast cancer, Shotz tonometry for glau-
coma, etc., but it has been very rarely applied in practice [10, 11]. There is a widespread percep-
tion that there needs to be a link between diagnosis and treatment, and it is generally accepted
that tests should not be used unless their results change patient management [21]. The mea-
surement of LS in patients with chronic hepatitis C seems to satisfy these requirements, and
the same method of defining cut-off values can also be applied to other validated non-invasive
tests for staging hepatitis C as FibroTest1, platelet ratio index (APRI) and FIB-4 or other liver
diseases such as chronic hepatitis B.
A possible limitation of our study is that as healthy controls we have used a population of
blood donors in whom the presence of latent liver disease cannot be absolutely excluded even
against their repeated normal blood tests.
Another limitation is that we have compared the TE LS values with the histologic findings
of liver biopsies, which are currently considered an imperfect reference standard as they lead to
a false negative rate of 20% in the case of a diagnosis of severe fibrosis [23–27]. It is possible
that some of the LS results were classified as false positive whereas they may be in fact true pos-
itive and false negative at biopsy histology, meaning that the specificity of LS measurements
has been possibly underestimated despite our efforts to reduce biopsy sampling errors by
accepting adequately sized specimens only. However, in order to counteract the possible
underestimation of this specificity, the recommended cut-off values would have been even
lower. Of note, we have used inclusion criteria requiring ALT elevation>1.5 ULN, which is no
more required.
A further possible shortcoming of this study is that the estimated H/B ratios (Table 3) were
obtained on the basis of the holistic clinical judgement of the specialists working in the partici-
pating centers, and are therefore a potential source of heterogeneity. However, it is unlikely
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that the alternative approach of building a more formal cost/benefit analysis would have
addressed such an issue because there is little data concerning the natural history of hepatitis C
or the extent of benefit or harm arising from treatment [22]. Interestingly, in the literature
there are several examples supporting clinical judgment as a valid approach to complex clinical
decisions [28, 29].
In conclusion, we suggest that a “one cut-off value fits all” approach is not appropriate, espe-
cially when the results of a single test are the major driver of a clinical decision, and that cut-off
values should vary depending on the H/B profile of the proposed/available treatments. Given
that for the IFN-free regimens of chronic hepatitis C treatment the benefits largely exceed the
harms, the LS values justifying treatment initiation are lower than those computed on the basis
of diagnostic accuracy, independently of the liver fibrosis score.
Specifically, our study emphasizes that in the setting of IFN-free regimens the values of LS
indicating the need to start antiviral treatment are sensibly lower than those used only to maxi-
mize diagnostic accuracy as usually incorporated in the clinical guidelines. Thus, in the context
of economic constraints the decision to treat or not to treat should be based on clinical consid-
erations and the assessment of LS should be re-interpreted. From a practical viewpoint, when
limited resources preclude the treatment of all patients, independently from the severity of the
disease, an appropriate prioritization strategy is needed. Compared to the current cut-off set at
10 kPa chosen in most European countries, a new cut-off value defined on the basis of the
expected harm/benefit ratio would reduce the number of inappropriately untreated patients,
i.e. the false negative results.
On the other hand, in those national health system enjoying a more favorable level of
resources and where the access to IFN-free regimens is broader, including also patients with
mild to moderate, or absent fibrosis, LS determination by TE is not helpful or justified.
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